Insomnia: Pharma Wakes Up to the Next Huge CNS Market
The insomnia market is entering a growth spurt enabled and fueled by more effective and safer drugs and their intense promotion: think depression in 1990, without the social stigma. The recent launch of three new products-Sepracor Inc.'s eszopiclone (Lunesta), Takeda Pharmaceutical Co. Ltd.'s ramelteon (Rozerem) and Sanofi-Aventis' controlled-release zolpidem (Ambien CR)-and the advertising blitz that has accompanied Lunesta and Ambien CR, has brought the plight of insomnia sufferers to the fore. And as it grows, market shares in insomnia can shift quickly.
By Christopher Morrison
Count yourself lucky if you've had a good night's sleep. The insomnia market, it seems, is entering a growth spurt enabled and fueled by more effective and safer drugs and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
